Monday, 6 Oct 2025
  • About Us
  • Contact Us
  • Terms and Conditions
  • Privacy Policy
Subscribe
Life Care News
  • Home
  • Business
    • Business Wire
    • Globenews Wire
  • News
    NewsShow More
    HKUST Scientists Reveal Critical Impacts of a Chinese Genetic Risk Factor in Alzheimer’s Disease
    HKUST Scientists Reveal Critical Impacts of a Chinese Genetic Risk Factor in Alzheimer’s Disease
    05/10/2025
    GSME Acquires Muse Semiconductor
    GSME Acquires Muse Semiconductor
    05/10/2025
    Cummins India Limited Commemorates 30 Years of Listing on NSE
    Cummins India Limited Commemorates 30 Years of Listing on NSE
    04/10/2025
    Black Box Partners with Wind River to Accelerate Edge and Cloud Innovation Globally
    Black Box Partners with Wind River to Accelerate Edge and Cloud Innovation Globally
    04/10/2025
    10 Icons Who Inspire Change: A Celebration of Vision, Commitment & Legacy
    10 Icons Who Inspire Change: A Celebration of Vision, Commitment & Legacy
    03/10/2025
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
  • 🔥
  • news
  • global
  • Business
  • june
  • announced
  • today
  •  and
  • july
  •  the
  • company
Font ResizerAa
Life Care NewsLife Care News
  • Home
  • Business
  • News
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
Search
  • Home
  • Business
    • Business Wire
    • Globenews Wire
  • News
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
Follow US
© 2022 Foxiz News Network. Ruby Design Company. All Rights Reserved.
Health

Spineway : H1 2025 results – Continued improvement in results and financial position

GlobeNews Wire
Last updated: 31/07/2025 1:19 AM
GlobeNews Wire
Share
6 Min Read
Spineway : H1 2025 results – Continued improvement in results and financial position
SHARE
Spineway : H1 2025 results – Continued improvement in results and financial position

Press release        

Ecully, July 30, 2025 – 7 p.m.

SPINEWAY

H1 2025 results 

  • Continued improvement in results and financial position
  • Full-year 2025 growth target confirmed
In thousands of euros

Consolidated financial statements – Unaudited

H1 2025 H1 2024
Revenue 5,573 6,535
Cost of sales (1,702) (2,059)
Gross margin

% of revenue

3,870

69%

4,476

68%

Net operating expenses

Of which general operating costs

(5,068)

(2,086)

(5,246)

(2,232)

Of which personnel expenses (2,374) (2,685)
Operating income/(loss) (1,197) (770)
Financial income/(expense)

Including the Negma exceptional financial expense1

(219) (2,096)

(1,467)

Non-recurring income/(expenses) 0 (515)
Net income/(loss)

Of which adjusted net income/(loss)2

(1,416)

(1,416)

(3,381)

(1,914)

The Board of Directors of Spineway, meeting on July 30, 2025 under the chairmanship of Stéphane Le Roux, approved the financial statements for the six months to June 30, 2025.

Spineway, a specialist in innovative implants for the treatment of severe spine disorders, recorded revenue of €2.7 million in the second quarter of 2025, down from €3.5 million in the same period in 2024, but broadly in line with the quarterly revenue recorded since the third quarter of 2024. Revenue for the first half of 2025 accordingly totaled €5.6 million, compared with €6.5 million for the same period last year, reflecting particularly high activity in the first half of 2024 (up 20%). However, the deferral of major account orders to the second half of 2025 enables Spineway to confirm its full-year revenue growth target for 2025.

€2 million improvement in net result
Operating performance improved in the first half of 2025 compared with 2024, with a 1-point improvement in gross margin to 69% and a 3% reduction in net operating costs. The cost-cutting measures implemented last year resulted in a €311 thousand (-12%) reduction in personnel expenses and a €146 thousand (-7%) reduction in general operating costs.

Financial expense related to the Negma bond financing was significantly reduced, resulting in a €1.9 million reduction in the financial loss to €219 thousand.

As a result, the net loss narrowed by €2 million to €1.4 million in the six months to June 30, 2025, from €3.4 million in 2024.

Solid €4 million cash position as of 30 June 2025; end of 2023 bond financing agreement

The convertible bond (OCA) issue and subscription agreement entered into with Negma in 20233 expired in May 2025. In the first half of 2025, 180 OCAs were issued and 235 OCAs were converted into 6,752,115 shares, representing a capital increase of €13,504.23. As a result, Spineway’s share capital as of June 30, 2025 amounted to €71,088.78, divided into 35,544,391 shares with a par value of €0.002 each.

Spineway’s effective control of expenditure has enabled it to report a solid cash position of €4 million as of June 30, 2025, i.e. a net cash burn of €0.5 million since December 31, 2024. This is primarily due to a doubling of capital expenditure in the first half of the year, reaching €0.8 million, in connection with the completion of the new industrial tool dedicated to the production of ESP4 intervertebral disc prostheses. This new production line will give the Group greater flexibility and responsiveness, thereby improving its competitiveness in this range of implants.

As of June 30, 2025, financial debt stood at €1.5 million, with net cash (after deducting financial debt) totalling €2.5 million.

Full-year 2025 revenue growth target confirmed

During the first half of 2025, Spineway laid the foundations for sustained growth in international markets through an intensive global training program that enabled over 100 surgeons to be trained across Europe, Asia, and Latin America,5 and through the commercial launch of the ESP product range in Indonesia.

With solid financial foundations and strong commercial momentum, Spineway is entering the second half of 2025 with confidence and determination.

Next event:
October 14, 2025 – Q3 2025 revenue

SPINEWAY IS ELIGIBLE FOR PEA-SME (EQUITY SAVINGS PLANS FOR SMES)
Find out all about Spineway at www.spineway.com

This press release has been prepared in both English and French. In case of discrepancies, the French version shall prevail.

Spineway designs, manufactures and markets innovative implants and surgical instruments for treating severe disorders of the spinal column.
Spineway has an international network of over 50 independent distributors and more than 70% of its revenue comes from exports.
ISIN: FR001400N2P2 – ALSPW 

Contacts:

SPINEWAY

Shareholder-services line

Available Tuesday through Thursday

+33 (0)806 706 060

AELIUM

Investor relations

Solène Kennis

spineway@aelium.fr


1 The Negma financing agreement provided for compensation if the share price fell below the nominal value of the share. The unfavorable trend affecting Spineway’s share price at the beginning of 2024 resulted in compensation as tranches were drawn down.
2 Net income/(loss) restated for the Negma exceptional financial expense
3 Press release of May 25, 2023
4 Press release of July 03, 2025
5 Press release of July 25, 2025

  • CP_SPW-RS2025_EN_VF
Wynn Unveils “Wynn Signature – 2025 Hypercar Exhibition” with Spectacular Fanfare to Elevate the Exhibition Experience
COLGATE DENTAL VEER ANTHEM LAUNCHED TO EMPOWER KIDS TO BE THEIR OWN HEROES OF ORAL HEALTH
NYSE Content Advisory: Pre-Market update + The Walt Disney Company rings Opening Bell to celebrate Disneyland Resort’s 70th anniversary
Pictor Secures Funding to Accelerate U.S. Expansion through Partner-Informed Proteomics Solutions
SquaredFinancial doubles affiliates rewards with new CPA program, up to $2,500 per referral
TAGGED: and2025AdventurecontinuedecullyfinancialFR0011398874improvementjulynewsParis:ALSPWpositionpressreleaseresultsspineway
Share This Article
Facebook Copy Link Print
- Advertisement -

Your Trusted Source for Accurate and Timely Updates!

Our commitment to accuracy, impartiality, and delivering breaking news as it happens has earned us the trust of a vast audience. Stay ahead with real-time updates on the latest events, trends.
FacebookLike
XFollow
PinterestPin
InstagramFollow
YoutubeSubscribe
LinkedInFollow
MediumFollow

Most Selling Products

Top Picks, Trending Now – Discover the Best Sellers!
Tecno Camon 20 Premier 5G

Tecno Camon 20 Premier 5G

Dark Welkin | 8GB RAM + 512GB Storage (Expandable RAM up to 16GB) | Industry’s 1st 50MP RGBW-Pro Camera | Segment-First 108MP Ultra-Wide Macro Lens | 6.67" 120Hz 10-bit AMOLED In-Display

iQOO Z10 Lite 5G

iQOO Z10 Lite 5G

Titanium Blue | 6GB RAM + 128GB Storage | Dimensity 6300 5G with 433K+ AnTuTu Score | Robust 6000mAh Battery | IP64 Rated + Military-Grade Shock Resistance

OnePlus 13s

OnePlus 13s

Black Velvet | 12GB RAM + 256GB Storage | Flagship Snapdragon® 8 Elite Chipset | Exceptional Battery Life in a Compact Form | Lifetime Display Warranty Included

Samsung Galaxy A55 5G

Samsung Galaxy A55 5G

Awesome Iceblue | 8GB RAM + 256GB Storage | Premium Metal Frame | 50MP OIS Main Camera with Nightography | IP67 Water & Dust Resistance | Gorilla Glass Victus+ | sAMOLED Display with Vision Booster

You Might Also Like

ArkBio’s Ziresovir Included into Pediatric RSV Drug Priority List by WHO
Health

ArkBio’s Ziresovir Included into Pediatric RSV Drug Priority List by WHO

16/07/2025
JointCommerce Launches A21+ Zero Party Data Community Digital Advertising Platform for Retailers, Brands, and Consumers
Tech

JointCommerce Launches A21+ Zero Party Data Community Digital Advertising Platform for Retailers, Brands, and Consumers

07/09/2025
NETSCOUT Earns Frost & Sullivan’s 2025 MENA Technology Innovation Leadership Recognition for Excellence in Cybersecurity Solutions
Entertainment

NETSCOUT Earns Frost & Sullivan’s 2025 MENA Technology Innovation Leadership Recognition for Excellence in Cybersecurity Solutions

13/07/2025
NETSOL Chosen by Sonic Automotive to Power Next-Gen Digital Retail Experience
Tech

NETSOL Chosen by Sonic Automotive to Power Next-Gen Digital Retail Experience

26/08/2025
Life Care News
Facebook Twitter Youtube Rss Medium

Life Care News:


We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.

Top Categories
  • Home
  • Business
  • News
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
Usefull Links
  • About Us
  • Contact Us
  • Terms and Conditions
  • Privacy Policy
Copyright © 2015 – 2025 LifeCareNews Network. All Rights Reserved. LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Life Care NewsLife Care News
Copyright © 2015 - 2025 LifeCareNews Network. All Rights Reserved. LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?